Skip to main navigation Skip to search Skip to main content

Circulating medium- and long-chain acylcarnitines are associated with plasma P-tau181 in cognitively normal older adults

  • Tahmida Sharmin
  • , Pratishtha Chatterjee
  • , James D. Doecke
  • , Nicholas J. Ashton
  • , Kevin Huynh
  • , Steve Pedrini
  • , Hamid R. Sohrabi
  • , Benjamin Heng
  • , Shaun Eslick
  • , Henrik Zetterberg
  • , Kaj Blennow
  • , Manohar Garg
  • , Ralph N. Martins*
  • *Corresponding author for this work
  • Macquarie University
  • Rajshahi University
  • University of Melbourne
  • CSIRO
  • Edith Cowan University
  • University of Gothenburg
  • King's College London
  • Baker Heart and Diabetes Institute
  • Alzheimer's Research Australia
  • Murdoch University
  • Sahlgrenska University Hospital
  • University College London
  • Clear Water Bay
  • University of Wisconsin-Madison

Research output: Contribution to journalArticleAcademicpeer-review

59 Downloads (Pure)

Abstract

Alzheimer's disease (AD) pathogenesis involves dysregulation in diverse biochemical processes. Nevertheless, plasma tau phosphorylated at threonine 181 (P-tau181), a recognised AD biomarker, has been described to reflect early-stage cortical amyloid-β (Aβ) deposition in cognitively normal (CN) adults. Therefore, identifying changes in plasma metabolites associated with plasma P-tau181 at the pre-clinical stage may provide insights into underlying biochemical mechanisms to better understand initial AD pathogenesis. In the current study, plasma P-tau181, quantified via single molecule array (Simoa) technology, and plasma metabolites, quantified via targeted-mass spectrometry, were investigated for associations in CN older adults and upon stratification by positron emission tomography (PET)-Aβ load. In addition, the P-tau181-linked metabolites were evaluated for cognitive performance and neuroimaging markers of AD and the potential to distinguish between CN Aβ− and CN Aβ+ individuals. Significant positive associations of medium- and long-chain acylcarnitines (ACs) were observed with P-tau181 in the entire cohort, CN Aβ− and CN Aβ+, suggesting a link between initial Aβ pathology and fatty acid oxidation-mediated energy metabolism pathways. However, in CN Aβ−, additional linear associations of P-tau181 were observed with muscle metabolism and nitric oxide homeostasis-associated metabolites. Upon investigating the P-tau181-linked metabolites for cognitive performance, significant inverse correlations of the verbal and visual episodic memory and the global composite score were noted in CN Aβ+ with medium- and long-chain ACs, suggesting prognostic value of ACs accompanying weaker cognitive performance. While investigating neuroimaging markers, ACs had positive associations with PET-Aβ load and inverse associations with hippocampal volume in CN Aβ+, indicating connections of ACs with initial AD pathogenesis. Furthermore, based on receiver operating characteristics analysis, the associated ACs potentially classified PET-Aβ status in older adults. Therefore, plasma P-tau181-linked circulating ACs may serve as potential prognostic markers for initial AD pathogenesis in CN older adults. However, further cross-sectional and longitudinal research in highly characterised AD cohorts is needed to validate current findings. (Figure presented.)
Original languageEnglish
JournalJournal of neurochemistry
Early online date2024
DOIs
Publication statusE-pub ahead of print - 2024
Externally publishedYes

Keywords

  • Alzheimer's disease
  • P-tau181
  • acylcarnitines
  • biomarkers
  • cognitively normal older adults
  • initial pathogenesis

Fingerprint

Dive into the research topics of 'Circulating medium- and long-chain acylcarnitines are associated with plasma P-tau181 in cognitively normal older adults'. Together they form a unique fingerprint.

Cite this